ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China · Delayed Price · Currency is CNY 10.68
+0.11 (1.04%)
At close: Feb 4, 2026
SHE:300254 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 844.99 | 842.33 | 792.42 | 824.84 | 924.94 | 822.33 |
Other Revenue | 4.28 | 4.28 | 6.89 | 4.15 | 5.43 | 25.74 |
| 849.26 | 846.61 | 799.31 | 829 | 930.37 | 848.07 | |
Revenue Growth (YoY) | 1.57% | 5.92% | -3.58% | -10.90% | 9.71% | -25.07% |
Cost of Revenue | 279.6 | 283.21 | 259.45 | 251.21 | 290.06 | 264.55 |
Gross Profit | 569.66 | 563.39 | 539.86 | 577.79 | 640.32 | 583.52 |
Selling, General & Admin | 413.89 | 428.41 | 453.44 | 534.1 | 603.92 | 693.14 |
Research & Development | 57.39 | 56.53 | 49.97 | 54.52 | 57.12 | 72.39 |
Other Operating Expenses | 17.18 | 9.71 | 11.78 | 12.09 | 12.77 | 11.22 |
Operating Expenses | 494.29 | 500.43 | 514.76 | 601.43 | 668.48 | 781.85 |
Operating Income | 75.37 | 62.97 | 25.1 | -23.64 | -28.16 | -198.33 |
Interest Expense | -22.26 | -16.98 | -33.16 | -46.06 | -49.17 | -54.68 |
Interest & Investment Income | 2.84 | 5.86 | 24.63 | 2.55 | 15.74 | 1.5 |
Earnings From Equity Investments | - | - | - | -3.43 | - | - |
Currency Exchange Gain (Loss) | - | - | 0.01 | 0.62 | 0 | 0.01 |
Other Non Operating Income (Expenses) | -5.35 | -0.18 | 2.44 | -2.08 | -0.2 | -1.08 |
EBT Excluding Unusual Items | 50.6 | 51.68 | 19.02 | -72.05 | -61.8 | -252.59 |
Impairment of Goodwill | -4.26 | -4.26 | -4.1 | -19.58 | -19.6 | -58.62 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.22 |
Gain (Loss) on Sale of Assets | 8.04 | 7.51 | 18.8 | 0.69 | -0.37 | 0.01 |
Asset Writedown | 1.79 | -1.41 | -1.4 | -28.82 | -12.08 | -18.03 |
Other Unusual Items | 28.44 | 27.13 | 22.97 | 29.74 | 28.37 | 31.06 |
Pretax Income | 84.6 | 80.64 | 55.28 | -90.02 | -65.48 | -298.39 |
Income Tax Expense | 28.53 | 5.88 | 6.55 | 7.9 | 9.07 | -17.82 |
Earnings From Continuing Operations | 56.07 | 74.76 | 48.73 | -97.92 | -74.55 | -280.57 |
Minority Interest in Earnings | -35.71 | -32.57 | -23.53 | -20.6 | -16.89 | 18.2 |
Net Income | 20.36 | 42.19 | 25.2 | -118.52 | -91.44 | -262.37 |
Net Income to Common | 20.36 | 42.19 | 25.2 | -118.52 | -91.44 | -262.37 |
Net Income Growth | -75.48% | 67.45% | - | - | - | - |
Shares Outstanding (Basic) | 242 | 242 | 242 | 237 | 228 | 213 |
Shares Outstanding (Diluted) | 244 | 242 | 242 | 237 | 228 | 213 |
Shares Change (YoY) | 0.95% | 0.20% | 1.89% | 4.00% | 6.92% | 2.25% |
EPS (Basic) | 0.08 | 0.17 | 0.10 | -0.50 | -0.40 | -1.23 |
EPS (Diluted) | 0.08 | 0.17 | 0.10 | -0.50 | -0.40 | -1.23 |
EPS Growth | -75.71% | 67.11% | - | - | - | - |
Free Cash Flow | 64.2 | 19.44 | 3.9 | 48.09 | 59.99 | -52.34 |
Free Cash Flow Per Share | 0.26 | 0.08 | 0.02 | 0.20 | 0.26 | -0.24 |
Gross Margin | 67.08% | 66.55% | 67.54% | 69.70% | 68.82% | 68.81% |
Operating Margin | 8.88% | 7.44% | 3.14% | -2.85% | -3.03% | -23.39% |
Profit Margin | 2.40% | 4.98% | 3.15% | -14.30% | -9.83% | -30.94% |
Free Cash Flow Margin | 7.56% | 2.30% | 0.49% | 5.80% | 6.45% | -6.17% |
EBITDA | 124.97 | 113.85 | 77.69 | 34.66 | 35.55 | -133.51 |
EBITDA Margin | 14.71% | 13.45% | 9.72% | 4.18% | 3.82% | -15.74% |
D&A For EBITDA | 49.59 | 50.88 | 52.59 | 58.3 | 63.71 | 64.82 |
EBIT | 75.37 | 62.97 | 25.1 | -23.64 | -28.16 | -198.33 |
EBIT Margin | 8.88% | 7.44% | 3.14% | -2.85% | -3.03% | -23.39% |
Effective Tax Rate | 33.73% | 7.29% | 11.85% | - | - | - |
Revenue as Reported | 849.26 | 846.61 | 799.31 | 829 | 930.37 | 848.07 |
Advertising Expenses | - | 12.74 | 5.67 | 4.88 | 8.44 | 12.64 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.